NRx Pharmaceuticals Subsidiary HOPE Therapeutics to Acquire Stake in Florida Psychiatry Clinic

HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals, has entered into a binding Letter of Intent to purchase a 49% interest in Cohen and Associates, LLC, a premier interventional psychiatry clinic in the Sarasota-Bradenton area. This clinic, established by Dr. Rebecca Cohen, specializes in advanced treatments for conditions such as suicidal depression, PTSD, and CNS disorders, utilizing therapies like ketamine, Spravato, and TMS. The acquisition is poised to serve as a cornerstone for HOPE's regional expansion, aligning with its commitment to providing compassionate, evidence-based mental health care. The finalization of the deal is contingent upon the completion of closing and definitive agreements.

NRx Pharmaceuticals is at the forefront of developing NMDA platform-based therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD. Among its pipeline is NRX-101, an investigational Breakthrough Therapy designated by the FDA for suicidal treatment-resistant bipolar depression and chronic pain, with plans underway for an NDA submission for Accelerated Approval. Additionally, NRx is advancing NRX-100 (IV ketamine) for suicidal depression treatment, leveraging data from clinical trials and a Fast Track Designation from the US FDA.